Protein detail
ITAX
Integrin alpha-X (CD11 antigen-like family member C) (Leu M5) (Leukocyte adhesion glycoprotein p150,95 alpha chain) (Leukocyte adhesion receptor p150,95) (CD antigen CD11c)
Protein symbol ITAX | UniProt ID | EVMP score 0.50 |
Frequency 2 | Transmembrane count 1 | Protein classification CD markersFDA approved drug targetsPredicted intracellular proteinsPredicted membrane proteins |
EVMP score: annotation confidence score.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40
Basic Information
Protein Names
Integrin alpha-X (CD11 antigen-like family member C) (Leu M5) (Leukocyte adhesion glycoprotein p150,95 alpha chain) (Leukocyte adhesion receptor p150,95) (CD antigen CD11c)
Protein Class
CD markersFDA approved drug targetsPredicted intracellular proteinsPredicted membrane proteins
Protein Function
- CD markers
- Predicted intracellular proteins
- FDA approved drug targets:Biotech drugs
Transmembrane
1108..1128; Helical
Transmembrane Count
1
Ensembl
Entrez Gene Symbol
Gene Synonym
CD11C
Gene Description
Integrin subunit alpha X
Chromosome
16
Position
31355134-31382999
Frequency
2
EVMP Score
0.50
Fluorescence & Localization
Tissue SpecificintestineCell SpecificColonocytesSingle-Nuclei Brain SpecificastrocyteSecretome LocationIntracellular and membraneSecretome FunctionTransport
Function & Pathway
Protein Function
- CD markers
- Predicted intracellular proteins
- FDA approved drug targets:Biotech drugs
Cellular Component
Molecular Function
Biological Process
KEGG
Reactome
- R-hsa-202733 cell surface interactions at the vascular wall
- R-hsa-1280215 cytokine signaling in immune system
- R-hsa-3000178 ecm proteoglycans
- R-hsa-1474244 extracellular matrix organization
- R-hsa-109582 hemostasis
- R-hsa-168249 innate immune system
- R-hsa-216083 integrin cell surface interactions
- R-hsa-6785807 interleukin 4 and interleukin 13 signaling
- R-hsa-6798695 neutrophil degranulation
- R-hsa-449147 signaling by interleukins
Mediation Categories
Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationImmune mediationReceptor-signaling mediation
Relations & Evidence
Enzyme-Mediated Modification
0 records.
Ligand-Receptor Signaling
57 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| receptor | receptor | CellPhoneDB | No | Yes | No | Yes | No |
| receptor | receptor | GO_Intercell | No | Yes | No | Yes | No |
| receptor | receptor | HPMR | No | Yes | No | Yes | No |
| receptor | receptor | ICELLNET | No | Yes | No | Yes | No |
| receptor | receptor | CellTalkDB | No | Yes | No | Yes | No |
| receptor | receptor | Surfaceome | No | Yes | No | Yes | No |
| receptor | receptor | Ramilowski2015 | No | Yes | No | Yes | No |
| receptor | receptor | LRdb | No | Yes | No | Yes | No |
| integrin | receptor | Integrins | No | Yes | No | Yes | No |
| integrin | receptor | UniProt_keyword | No | Yes | No | Yes | No |
Page 1 of 6Next
Regulatory Interaction Network
2 records.
| Source Protein Symbol | Source UniProt ID | Target Protein Symbol | Target UniProt ID | Is Directed | Is Stimulation | Is Inhibition | Database | References |
|---|---|---|---|---|---|---|---|---|
| FIBA | P02671 | ITAX | P20702 | Yes | Yes | No | Fantom5_LRdbCellTalkDBHPMR_LRdbiTALKHPMR_CellinkertalklrRamilowski2015SIGNORconnectomeDB2020CellinkerWangLRdbSTRING_talklrHPMR_talklr | CellTalkDB:4062888Cellinker:4062888LRdb:4062888connectomeDB2020:4062888SIGNOR:7679388 |
| ICAM1 | P05362 | ITAX | P20702 | Yes | Yes | No | Fantom5_LRdbCellTalkDBHPMR_LRdbiTALKtalklrRamilowski2015SIGNORconnectomeDB2020WangLRdbSTRING_talklrHPMR_talklr | SIGNOR:7679388LRdb:4062888connectomeDB2020:4062888 |
Protein Complex Composition
0 records.
Isolation & Detection Technology
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Protein Organic Solvent Precipitation | Mass spectrometry | 1 | 32384937 |
Sequence, Structure & Domains
Sequences
Length
1,163
Mass
127,829
Sequence
MTRTRAALLLFTALATSLGFNLDTEELTAFRVDSAGFGDSVVQYANSWVVVGAPQKITAANQTGGLYQCGYSTGACEPIGLQVPPEAVNMSLGLSLASTTSPSQLLACGPTVHHECGRNMYLTGLCFLLGPTQLTQRLPVSRQECPRQEQDIVFLIDGSGSISSRNFATMMNFVRAVISQFQRPSTQFSLMQFSNKFQTHFTFEEFRRSSNPLSLLASVHQLQGFTYTATAIQNVVHRLFHASYGARRDAAKILIVITDGKKEGDSLDYKDVIPMADAAGIIRYAIGVGLAFQNRNSWKELNDIASKPSQEHIFKVEDFDALKDIQNQLKEKIFAIEGTETTSSSSFELEMAQEGFSAVFTPDGPVLGAVGSFTWSGGAFLYPPNMSPTFINMSQENVDMRDSYLGYSTELALWKGVQSLVLGAPRYQHTGKAVIFTQVSRQWRMKAEVTGTQIGSYFGASLCSVDVDSDGSTDLVLIGAPHYYEQTRGGQVSVCPLPRGWRRWWCDAVLYGEQGHPWGRFGAALTVLGDVNGDKLTDVVIGAPGEEENRGAVYLFHGVLGPSISPSHSQRIAGSQLSSRLQYFGQALSGGQDLTQDGLVDLAVGARGQVLLLRTRPVLWVGVSMQFIPAEIPRSAFECREQVVSEQTLVQSNICLYIDKRSKNLLGSRDLQSSVTLDLALDPGRLSPRATFQETKNRSLSRVRVLGLKAHCENFNLLLPSCVEDSVTPITLRLNFTLVGKPLLAFRNLRPMLAADAQRYFTASLPFEKNCGADHICQDNLGISFSFPGLKSLLVGSNLELNAEVMVWNDGEDSYGTTITFSHPAGLSYRYVAEGQKQGQLRSLHLTCDSAPVGSQGTWSTSCRINHLIFRGGAQITFLATFDVSPKAVLGDRLLLTANVSSENNTPRTSKTTFQLELPVKYAVYTVVSSHEQFTKYLNFSESEEKESHVAMHRYQVNNLGQRDLPVSINFWVPVELNQEAVWMDVEVSHPQNPSLRCSSEKIAPPASDFLAHIQKNPVLDCSIAGCLRFRCDVPSFSVQEELDFTLKGNLSFGWVRQILQKKVSVVSVAEITFDTSVYSQLPGQEAFMRAQTTTVLEKYKVHNPTPLIVGSSIGGLLLLALITAVLYKVGFFKRQYKEMMEEANGQIAPENGTQTPSPPSEK
3D Structural Models
Turn
35..38; 45..47; 71..73; 100..103; 183..185; 237..240; 341..343; 560..562; 634..636; 662..664; 668..670; 693..695; 744..747; 854..857; 1022..1024; 1076..1078; 1150..1154; 1160..1162
Helix
164..178; 203..208; 212..216; 228..236; 242..244; 269..278; 290..293; 298..304; 310..312; 319..325; 326..334; 336..338; 372..375; 398..400; 427..429; 546..549; 574..577; 1010..1016; 1054..1058; 1086..1089; 1133..1144
Beta Strand
24..26; 28..31; 39..44; 48..59; 62..69; 75..78; 87..89; 94..99; 104..116; 119..129; 131..133; 136..141; 150..157; 186..201; 250..260; 282..289; 307..309; 313..318; 348..351; 354..361; 364..369; 379..381; 384..386; 389..391; 407..424; 432..439; 442..450; 460..465; 470..472; 475..484; 489..496; 508..510; 514..521; 523..529; 531..535; 538..543; 551..556; 569..573; 586..592; 595..599; 601..606; 609..615; 618..632; 641..643; 648..661; 673..682; 685..687; 696..706; 708..719; 726..728; 730..740; 760..765; 772..774; 782..786; 791..795; 800..808; 814..824; 827..829; 838..841; 847..853; 858..870; 875..884; 892..901; 908..910; 914..924; 926..930; 932..934; 937..941; 948..959; 961..963; 965..977; 980..989; 991..993; 999..1003; 1019..1021; 1025..1037; 1042..1053; 1062..1073; 1079..1081; 1090..1100; 1147..1149
3D Structure
NMR spectroscopy (1); X-ray crystallography (7)
Domain & Motif Annotations
Repeat
23..78; FG-GAP 1; 79..138; FG-GAP 2; 340..391; FG-GAP 3; 392..443; FG-GAP 4; 444..504; FG-GAP 5; 507..565; FG-GAP 6; 570..630; FG-GAP 7
Motif
1131..1135; GFFKR motif
Domain (CC)
The integrin I-domain (insert) is a VWFA domain. Integrins with I-domains do not undergo protease cleavage.
Domain (FT)
165..339; VWFA
Protein Families
Integrin alpha chain family
Sequence Similarities
Belongs to the integrin alpha chain family.
Clinical Relevance
Disease Involvement
FDA approved drug targets
Drug Targets
FDA approved drug targets